Information:
Fel:
ID
16673
Beskrivning
Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3; ODM derived from: https://clinicaltrials.gov/show/NCT00565396
Länk
https://clinicaltrials.gov/show/NCT00565396
Nyckelord
Versioner (1)
- 2016-07-31 2016-07-31 -
Uppladdad den
31 juli 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Chronic Kidney Insufficiency NCT00565396
Eligibility Chronic Kidney Insufficiency NCT00565396
- StudyEvent: Eligibility
Similar models
Eligibility Chronic Kidney Insufficiency NCT00565396
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
patients aged 18-75 years old
boolean
C0001779 (UMLS CUI [1])
Kidney Disease Secondary
Item
roll out secondary renal diseases
boolean
C0022658 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C0175668 (UMLS CUI [1,2])
Steroids Use | Immunosuppressive Agents Use
Item
do not use steroids and immunosuppresive drugs
boolean
C0038317 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C1524063 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Washout Period | Sitting diastolic blood pressure
Item
acei/arb treated patients should have 7-14 days wash out period，sidbp< 110mmhg
boolean
C0003015 (UMLS CUI [1])
C0521942 (UMLS CUI [2])
C1710661 (UMLS CUI [3])
C1319894 (UMLS CUI [4])
C0521942 (UMLS CUI [2])
C1710661 (UMLS CUI [3])
C1319894 (UMLS CUI [4])
Informed consent
Item
willing and able to comprehend and give written informed consent
boolean
C0021430 (UMLS CUI [1])
Clinical Study Follow-up Regular Willing
Item
willing to follow-up regularly
boolean
C3274571 (UMLS CUI [1,1])
C0205272 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
C0205272 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Steroids Use | Immunosuppressive Agents Use
Item
use steroids and immunosuppresive drugs
boolean
C0038317 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
C1524063 (UMLS CUI [1,2])
C0021081 (UMLS CUI [2,1])
C1524063 (UMLS CUI [2,2])
Kidney Disease Secondary
Item
secondary renal diseases
boolean
C0022658 (UMLS CUI [1,1])
C0175668 (UMLS CUI [1,2])
C0175668 (UMLS CUI [1,2])
Cardiovascular Diseases | Cerebrovascular Disorders
Item
acute cardio-cerebral diseases within 6 months
boolean
C0007222 (UMLS CUI [1])
C0007820 (UMLS CUI [2])
C0007820 (UMLS CUI [2])
Kidney Transplantation Post
Item
post renal transplantation
boolean
C0022671 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
pregnant/nursing women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Hypersensitivity Angiotensin-Converting Enzyme Inhibitors | Hypersensitivity Angiotensin II receptor antagonist
Item
history of hypersensitivity to acei/arb
boolean
C0020517 (UMLS CUI [1,1])
C0003015 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0521942 (UMLS CUI [2,2])
C0003015 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0521942 (UMLS CUI [2,2])
Study Subject Participation Status | Refusal to Participate
Item
refuse to join clinical trial
boolean
C2348568 (UMLS CUI [1])
C1136454 (UMLS CUI [2])
C1136454 (UMLS CUI [2])